ADIL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Adial Pharmaceuticals Inc (ADIL) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks strong positive catalysts, has weak financial performance, and no significant trading signals. It is better to hold off on investing in this stock at the moment.
The MACD is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral at 44.997, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels (Pivot: 1.685, R1: 1.819) and above the support level (S1: 1.551). Overall, the technical indicators suggest a weak trend with no clear buy signal.
The analyst maintains a Buy rating, citing the AUD opportunity and potential regulatory support for combating substance abuse.
The firm's price target was significantly reduced from $37.50 to $8 due to reverse split and expected dilution. Financial performance is weak with declining net income (-3.60% YoY) and EPS (-77.45% YoY). No recent news or significant trading trends from hedge funds, insiders, or Congress.
In Q4 2025, revenue remained at 0 with no growth. Net income dropped to -$1,996,163 (-3.60% YoY), and EPS fell to -1.82 (-77.45% YoY). Gross margin remained at 0 with no improvement. Overall, the financials indicate poor performance and lack of growth.
Maxim lowered the price target from $37.50 to $8 but maintained a Buy rating, citing potential opportunities in AUD and regulatory support. However, the reduced price target reflects concerns about reverse split and dilution.
